# A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI

Study · id `cardio:ct-nct01848106` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01848106](<https://clinicaltrials.gov/study/NCT01848106>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01848106

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 3232 participants.

## Technical summary

Registry record NCT01848106. Randomized; no masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3232 participants (enrolled count; ClinicalTrials.gov record NCT01848106, source copy `cardio:ctgov-nct01848106-2014-10-23`, retrieved 2026-10-26)
- Start date: 2013-09 (registry gives no type) (ClinicalTrials.gov record NCT01848106, source copy `cardio:ctgov-nct01848106-2014-10-23`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01848106, source copy `cardio:ctgov-nct01848106-2014-10-23`, retrieved 2026-10-26)
- Completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01848106, source copy `cardio:ctgov-nct01848106-2014-10-23`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01848106, source copy `cardio:ctgov-nct01848106-2014-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01848106-2014-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI
- Acronym: Regulate
- Condition: Coronary Artery Disease
- Intervention (Drug): pegnivacogin/anivamersen
- Intervention (Drug): Bivalirudin
- Lead sponsor: Regado Biosciences, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: The Cleveland Clinic
- Collaborator class: OTHER
- Collaborator: Duke Clinical Research Institute
- Collaborator class: OTHER
- Collaborator: Canadian VIGOUR Centre
- Collaborator class: OTHER
- Collaborator: Icahn School of Medicine at Mount Sinai
- Collaborator class: OTHER
- Collaborator: Parexel
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Bivalirudin (`cardio:bivalirudin`)
- Registry lists this organization as a collaborator: The Cleveland Clinic (`cardio:org-the-cleveland-clinic`)
- Registry lists this organization as a collaborator: Duke Clinical Research Institute (`cardio:org-duke-clinical-research-institute`)
- Registry lists this organization as a collaborator: Canadian VIGOUR Centre (`cardio:org-canadian-vigour-centre`)
- Registry lists this organization as a collaborator: Icahn School of Medicine at Mount Sinai (`cardio:org-icahn-school-of-medicine-at-mount-sinai`)
- Registry lists this organization as a collaborator: Parexel (`cardio:org-parexel`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial (`cardio:pubmed-26547100`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3c7a39eca60e785339196a0dc630b9f0ca2fb98a08127869973a4011166a9197
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
